Recent News

• 08.14.2025 - Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.14.2025 - Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 06.18.2025 - Discovery of First-in-Class Precision Antibody Drug Conjugates Targeting Mutant Calreticulin For the Treatment of Myeloproliferative Neoplasms
• 06.18.2025 - A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed / Refractory Lymphoid Malignancies: Updated Analysis
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.05.2025 - 2025 Jefferies Global Healthcare Conference
• 06.05.2025 - 2025 Jefferies Global Healthcare Conference
• 06.02.2025 - Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
• 06.02.2025 - Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Recent Filings

• 07.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 8-K Current report
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 3 Initial statement of beneficial ownership of securities